NCSZ}X.C2~7$~'X,#QGWJH:Y<T
SYSTEM PROCESSING...
NCSZ}X.C2~7$~'X,#QGWJH:Y<T
SYSTEM PROCESSING...
Posted: 2025-04-16 23:57:42 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-16 23:57:56 UTC
Verified By
Rollup News
Sotagliflozin, an SGLT inhibitor, significantly reduces heart attack and stroke risk in type 2 diabetes and kidney disease patients with cardiovascular risk factors.
Significant reduction in heart attack and stroke risk
Beneficial for type 2 diabetes and kidney disease patients
Offers a new treatment option for patients with cardiovascular risk factors